

# 2019-2020 Synagis® Seasonal Respiratory Syncytial Virus Enrollment Form



Fax Referral To: 1-800-323-2445

Email Referral To: customerservicefax@caremark.com

Phone: 1-800-237-2767

## Six Simple Steps to Submitting a Referral

### 1 PATIENT INFORMATION *(Complete or include demographic sheet)*

Patient Name: \_\_\_\_\_ Address: \_\_\_\_\_ City, State, ZIP: \_\_\_\_\_  
Preferred Contact Methods:  Phone (to primary # provided below)  Text (to cell # provided below)  Email (to email provided below)  
*Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.*  
Primary Phone: \_\_\_\_\_ Alternate Phone: \_\_\_\_\_ DOB: \_\_\_\_\_ Gender:  Male  Female  
Email: \_\_\_\_\_ Last Four of SSN: \_\_\_\_\_ Primary Language: \_\_\_\_\_

### 2 PRESCRIBER INFORMATION

Prescriber's Name: \_\_\_\_\_ State License #: \_\_\_\_\_  
NPI #: \_\_\_\_\_ DEA #: \_\_\_\_\_ Group or Hospital: \_\_\_\_\_  
Address: \_\_\_\_\_ City, State, ZIP: \_\_\_\_\_  
Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Contact Person: \_\_\_\_\_ Contact's Phone: \_\_\_\_\_

### 3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

Prescription Card:  
Name of Insurer: \_\_\_\_\_ ID#: \_\_\_\_\_ BIN: \_\_\_\_\_ PCN: \_\_\_\_\_ Group: \_\_\_\_\_  
Medical Insurance:  
Subscriber: \_\_\_\_\_ ID#: \_\_\_\_\_ Name of Insurer: \_\_\_\_\_ Phone: \_\_\_\_\_  
Secondary Insurance:  
Subscriber: \_\_\_\_\_ ID#: \_\_\_\_\_ Name of Insurer: \_\_\_\_\_ Phone: \_\_\_\_\_

### 4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: \_\_\_\_\_ Expected date of first injection: \_\_\_\_\_ Ship to:  Patient  Office  Other: \_\_\_\_\_

#### Diagnosis (ICD-10):

**Gestational Age:**  < 23 wks (P07.21)  23 wks (P07.22)  24 wks (P07.23)  25 wks (P07.24)  
 26 wks (P07.25)  27 wks (P07.26)  28 wks (P07.31)  29 wks (P07.32)  
 30 wks (P07.33)  31 wks (P07.34)  32 wks (P07.35)  33 wks (P07.36)  
 34 wks (P07.37)  35 wks (P07.38)

For additional ICD-10 information, please visit [CVS Specialty Healthcare Professionals Website](https://www.cvsspecialty.com/wps/portal/specialty/healthcare-professionals/about-us)

<https://www.cvsspecialty.com/wps/portal/specialty/healthcare-professionals/about-us>

#### Nursing:

No nursing coordination  Yes, CVS Specialty® to coordinate home health nurse visit for injection

#### **Chronic Respiratory Disease Arising in the Perinatal Period:**

Wilson-Mikity Syndrome (P27.0)  
 Bronchopulmonary Dysplasia originating in the perinatal period (P27.1)  
 Other chronic respiratory disease originating in the perinatal period (P27.8)

#### **Congenital Abnormality of Respiratory System:**

Congenital Subglottic Stenosis (Q31.1)  Other Congenital Malformations of Trachea (Q32.1)  
 Laryngocele (Q31.3)  Other Congenital Malformations of Bronchus (Q32.4)  
 Other Congenital Malformations of Larynx (Q31.8)  Congenital Cystic Lung (Q33.0)

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

**CONFIDENTIALITY NOTICE:** This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.

©2019 CVS Specialty and/or one of its affiliates. 75-38382A 071919

# 2019-2020 Synagis® Seasonal Respiratory Syncytial Virus Enrollment Form

## Please complete Patient and Prescriber information

Patient Name: \_\_\_\_\_ Patient DOB: \_\_\_\_\_  
 Prescriber Name: \_\_\_\_\_ Prescriber Phone: \_\_\_\_\_

### 4 DIAGNOSIS AND CLINICAL INFORMATION

Patient's Gestational Age (required): \_\_\_\_\_ weeks \_\_\_\_\_ days Patient's Birth Weight: \_\_\_\_\_ g / kg / lbs (please circle)  
 Current Weight: \_\_\_\_\_ g / kg / lbs (please circle) Date Recorded: \_\_\_/\_\_\_/\_\_\_\_\_  
 Did patient receive Synagis last season?  No  Yes Dates of Synagis doses given this season: \_\_\_\_\_  
 Multiple births:  No  Yes Enter names of Synagis candidates (submit separate enrollment forms): \_\_\_\_\_  
 Daycare attendance:  No  Yes School-age siblings in home:  No  Yes  
 NICU history:  No  Yes If yes, NICU name and include NICU summary: \_\_\_\_\_  
 Allergies: \_\_\_\_\_ Medical conditions not listed below: \_\_\_\_\_

**Clinical Conditions:** 2014 AAP Committee on Infectious Disease and Bronchiolitis Guidelines

#### Chronic Lung Disease (CLD):

< 12 months of age with CLD\*  
 < 24 months of age with CLD\* AND continues to require medical support during the 6-month period before second RSV season AND  
 Supplemental oxygen (dates) \_\_\_\_\_  Chronic corticosteroids (drugs/dates) \_\_\_\_\_  
 Diuretic therapy (drugs/dates) \_\_\_\_\_  Bronchodilators (drugs/dates) \_\_\_\_\_

\*CLD of prematurely defined as gestational age < 31 weeks, 6 days AND requirement for 21% oxygen for at least the first 28 days after birth

#### Congenital Heart Disease (CHD):

< 12 months of age at start of season with hemodynamically significant CHD such as:  
 Acyanotic heart disease and receiving medication to control congestive heart failure and surgery to correct (meds/dates) \_\_\_\_\_ (surgery date) \_\_\_\_\_  
 Moderate to severe pulmonary hypertension  
 Other: describe \_\_\_\_\_  
 < 24 months of age undergoing cardiac transplantation during the RSV season (date) \_\_\_\_\_  
 Cyanotic Heart Disease: diagnosis \_\_\_\_\_

#### Airway/Neuro-muscular Conditions:

< 12 months of age at start of season and compromised handling of secretions AND due to  
 Significant abnormality of the airway (attach clinical notes)  Neuromuscular condition (attach clinical notes)

**Prematurity:**  < GA 28 wks, 6 days AND < 12 months at start of season

**Other conditions:**  Other medical history (describe) \_\_\_\_\_

### 5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Synagis (palivizumab)	50 mg and/or 100 mg vials	<input type="checkbox"/> Inject 15 mg/kg IM one time per month <input type="checkbox"/> Other: _____	Quantity: QS to achieve 15 mg/kg dose Refills: _____
<input type="checkbox"/> Epinephrine	1:1000 amp	Inject 0.01 mg/kg SC as directed for anaphylaxis	Quantity: _____ Refills: 0

Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

Ancillary supplies and kits provided as needed for administration

### 6 PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED

(Date)

DISPENSE AS WRITTEN

(Date)

X \_\_\_\_\_ X \_\_\_\_\_

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

**CONFIDENTIALITY NOTICE:** This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.

©2019 CVS Specialty and/or one of its affiliates. 75-38382A 071919